Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Oct
27
Today In Oncology
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma: 9-Year Follow-Up of CheckMate 238
Disitamab Vedotin Plus Toripalimab vs Chemotherapy in HER2-Expressing Advanced Urothelial Cancer
Sacituzumab Tirumotecan in EGFR-Mutated Advanced NSCLC
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo